[Table_Summary] [Table_Title] 主动控量稳价，蓄力长远发展 [Table_ReportDate] 舍得酒业(600702)公司简评报告 | 2024.08.28 [Table_Rank] 评级： 增持 核心观点 [Table_Authors] 赵瑞 分析师 SAC 执证编号：S0110522120001 zhaorui@sczq.com.cn [Table_Chart] 市场指数走势（最近 1 年） 资料来源：聚源数据 -1 -0.5 0 0.5 28-Aug 8-Nov19-Jan 31-Mar 11-Jun 22-Aug 舍得酒业 沪深300 | --- | --- | |---------------------------------|--------------| | [Table_BaseData] 公司基本数据 | | | 最新收盘价（元） | 43.48 | | 一年内最高 / 最低价（元） | 149.06/43.10 | | 市盈率（当前） | 10.04 | | 市净率（当前） | 2.07 | | 总股本（亿股） | 3.33 | | 总市值（亿元） | 1 ...

Investment Rating - Buy rating [1] Core Views - The company reported outstanding performance in the first half of 2024, with total operating revenue reaching RMB 65.044 billion, a year-on-year increase of 489.58% Net profit attributable to the parent company was RMB 1.625 billion, turning a profit compared to the same period last year [3] - In Q2 2024, the company achieved revenue of RMB 38.484 billion, up 547.7% year-on-year and 44.9% quarter-on-quarter Net profit attributable to the parent company for Q2 was RMB 1.405 billion, and adjusted net profit was RMB 1.323 billion [3] - The scale effect in Q2 2024 has gradually released profitability, with new energy vehicle sales becoming the main driver of growth The company sold 200,900 new energy vehicles in the first half of 2024, a year-on-year increase of 348.55% [3] - The gross profit margin for the first half of 2024 increased to 25.04%, with Q2 2024 gross margin reaching 27.47%, up 23.3 percentage points year-on-year and 5.96 percentage points quarter-on-quarter [3] - The AITO brand, particularly the flagship model M9, has been a significant highlight, with cumulative orders exceeding 120,000 units, showcasing strong competitiveness in the luxury vehicle market [3] - The company acquired a 10% equity stake in Yinwang for RMB 1.8 billion, strengthening its strategic partnership with Huawei and enhancing profitability [3] Financial Performance and Projections - Revenue for 2024 is projected to be RMB 147.1 billion, with net profit attributable to the parent company expected to reach RMB 5.07 billion [3] - Revenue for 2025 is forecasted to be RMB 166.87 billion, with net profit attributable to the parent company expected to be RMB 7.8 billion [3] - Revenue for 2026 is projected to be RMB 190.91 billion, with net profit attributable to the parent company expected to reach RMB 9.83 billion [3] - EPS for 2024 is estimated at RMB 3.36, increasing to RMB 5.17 in 2025 and RMB 6.51 in 2026 [3] - The company's gross profit margin is expected to remain stable at around 25.2% to 25.9% from 2024 to 2026 [4] Key Financial Ratios - ROE is projected to be 31.2% in 2024, 33.9% in 2025, and 31.4% in 2026 [4] - ROIC is expected to be 35.3% in 2024, 37.0% in 2025, and 33.6% in 2026 [4] - The debt-to-asset ratio is forecasted to decrease from 91.5% in 2024 to 86.3% in 2026 [4] - The current ratio is expected to improve from 0.95 in 2024 to 1.07 in 2026 [4] Valuation Metrics - The P/E ratio is projected to decrease from 23.4 in 2024 to 12.1 in 2026 [4] - The P/B ratio is expected to decline from 7.30 in 2024 to 3.79 in 2026 [4]

[Table_Summary] [Table_Title] 打造人工智能时代的"机器人与 AI 视觉产业中台" [Table_ReportDate] 奥比中光(688322)公司简评报告 | 2024.08.28 [Table_Rank] 评级： 买入 核心观点 [Table_Authors] 何立中 电子行业首席分析师 SAC 执证编号：S0110522110002 helizhong@sczq.com.cn 电话：010-81152682 [Table_Chart] 市场指数走势（最近 1 年） -0.5 0 0.5 28-Aug 9-Nov21-Jan 3-Apr15-Jun 27-Aug 奥比中光 沪深300 资料来源：聚源数据 | --- | --- | |---------------------------------|-------------| | [Table_BaseData] 公司基本数据 | | | 最新收盘价（元） | 24.03 | | 一年内最高 / 最低价（元） | 36.33/18.83 | | 市盈率（当前） | -50.85 | | 市净率（当前） | 3.25 | | ...

[Table_Summary] [Table_Rank] 评级： 买入 [Table_Authors] 王斌 首席分析师 SAC 执证编号：S0110522030002 wangbin3@sczq.com.cn 电话：86-10-81152644 [Table_Chart] 市场指数走势（最近 1 年） -0.5 0 0.5 1 29-Aug 10-Nov 22-Jan 4-Apr16-Jun 28-Aug 艾迪药业 沪深300 资料来源：聚源数据 | --- | --- | |---------------------------------|------------| | [Table_BaseData] 公司基本数据 | | | 最新收盘价（元） | 7.96 | | 一年内最高 / 最低价（元） | 17.40/7.41 | | 市盈率（当前） | -29.93 | | 市净率（当前） | 3.09 | | 总股本（亿股） | 4.21 | | 总市值（亿元） | 33.49 | | 资料来源：聚源数据 | | 相关研究 [Table_OtherReport] 艾迪药业：创新药销售持续改善，进 入快速 ...

[Table_Summary] [Table_Title] 布局多应用场景，丰富产品矩阵 [Table_ReportDate] 南芯科技(688484)公司简评报告 | 2024.08.29 [Table_Rank] 评级： 买入 核心观点 [Table_Authors] 何立中 电子行业首席分析师 SAC 执证编号：S0110522110002 helizhong@sczq.com.cn 电话：010-81152682 [Table_Chart] 市场指数走势（最近 1 年） -0.5 0 0.5 29-Aug 10-Nov 22-Jan 4-Apr16-Jun 28-Aug 南芯科技 沪深300 资料来源：聚源数据 | --- | --- | |---------------------------------|-------------| | [Table_BaseData] 公司基本数据 | | | 最新收盘价（元） | 27.08 | | 一年内最高 / 最低价（元） | 49.47/21.82 | | 市盈率（当前） | 31.35 | | 市净率（当前） | 2.99 | | 总股本（亿股） | ...

[Table_Title] 1 7 月上市公司出栏量稳健，近一周猪价呈震荡态势 [Table_ReportDate] 农林牧渔 | 行业简评报告 | 2024.08.28 核心观点 [Table_Rank] 评级： 看好 [Table_Authors] 赵瑞 分析师 SAC 执证编号：S0110522120001 zhaorui@sczq.com.cn [Table_Chart] 市场指数走势（最近 1 年） -0.3 -0.2 -0.1 0 0.1 农林牧渔 沪深300 28-Aug 8-Nov19-Jan 31-Mar 11-Jun 22-Aug 资料来源：聚源数据 相关研究 [Table_OtherReport] 猪价再创年内新高，7 月规模场出栏稳 健 短期猪价预计窄幅震荡，建议逢低布 局 猪价持续上涨，建议关注低估值高成 长标的 [Table_Summary] ⚫ 生猪养殖：据搜猪网，2024 年 8 月 26 日全国生猪出栏均价 20.10 元/公斤，周环比下降 2.24%。根据统计的 17 家生猪养殖上市公司 7 月份出栏情况来看，与 6 月份出栏数据相比，其中牧原、大北农、 立华股份、金新农出 ...

[Table_Rank] 评级： 看好 [Table_Authors] 赵瑞 分析师 SAC 执证编号：S0110522120001 zhaorui@sczq.com.cn [Table_Summary] [Table_Chart] 市场指数走势（最近 1 年） -0.4 -0.2 0 0.2 食品饮料 沪深300 28-Aug 9-Nov21-Jan 3-Apr15-Jun 27-Aug 资料来源：聚源数据 相关研究 [Table_OtherReport] 酒企龙头经营韧性较强，食品新品类 打开成长空间 酒企龙头发力三季度，大众品重视成 长赛道 板块震荡调整，关注中报景气方向 [Table_ReportDate] 食品饮料 | 行业简评报告 | 2024.08.28 核心观点 ⚫ 白酒市场：近期部分白酒上市公司发布中报，业绩表现有所分化。头 部酒企品牌优势彰显，业绩延续高质量增长，部分地产酒龙头经营表 现稳健，延续良好的增长势能。次高端品牌业绩相对承压，舍得酒业 24H1 营收、归母净利同比下滑较明显，由于上半年次高端白酒商务需 求不及预期，公司主动采取控量稳价策略，积极协助经销商提升动销， 对次高端大单品 ...

Investment Rating - The investment rating for the company is "Buy" [2] Core Views - The company reported a revenue of 31.993 billion yuan for the first half of 2024, a year-on-year decrease of 9.16%, while the net profit attributable to shareholders was 2.841 billion yuan, an increase of 6.1% year-on-year. In Q2 2024, revenue was 18.136 billion yuan, down 6.19% year-on-year but up 30.88% quarter-on-quarter, with a net profit of 1.382 billion yuan, up 25.01% year-on-year but down 5.32% quarter-on-quarter [2][4] - The main products, including ammonium phosphate, compound fertilizer, urea, and others, showed stable production and sales, with ammonium phosphate prices remaining at a high level. The average prices for the main products were 3,436 yuan/ton for ammonium phosphate, 2,985 yuan/ton for compound fertilizer, and 2,176 yuan/ton for urea, with sales volumes showing growth for most products [2][4] - The company has good financial control, maintaining low rates for sales, management, and finance at 1.14%, 1.89%, and 0.87% respectively, with a decrease in financial costs and optimized debt structure [3][4] - The phosphate rock market remains strong, with an average price of 1,011 yuan/ton for 30% grade phosphate rock. The company has significant phosphate reserves of nearly 800 million tons and a self-sufficiency rate in phosphate rock production, benefiting from its integrated mining and fertilizer operations [4] - The company is expected to achieve net profits of 4.966 billion yuan, 5.249 billion yuan, and 5.563 billion yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 2.71 yuan, 2.86 yuan, and 3.03 yuan, indicating a favorable outlook for the company as a leading player in the domestic phosphate chemical industry [4][5] Summary by Sections Financial Performance - In the first half of 2024, the company achieved a revenue of 31.993 billion yuan, a decrease of 9.16% year-on-year, and a net profit of 2.841 billion yuan, an increase of 6.1% year-on-year. Q2 2024 saw a revenue of 18.136 billion yuan, down 6.19% year-on-year but up 30.88% quarter-on-quarter, with a net profit of 1.382 billion yuan, up 25.01% year-on-year [2][4] Product Pricing and Sales - The average prices for the main products were 3,436 yuan/ton for ammonium phosphate, 2,985 yuan/ton for compound fertilizer, and 2,176 yuan/ton for urea, with sales volumes showing growth for most products. The company’s core product, ammonium phosphate, maintained a relatively high price level, and sales increased as demand is expected to rise with the upcoming autumn fertilization season [2][4] Financial Management - The company maintained low sales, management, and financial expense ratios at 1.14%, 1.89%, and 0.87% respectively, with a focus on controlling financial costs and optimizing the debt structure [3][4] Market Outlook - The phosphate rock market continues to be robust, with an average price of 1,011 yuan/ton for 30% grade phosphate rock. The company has substantial phosphate reserves and a high self-sufficiency rate in phosphate rock production, positioning it well to benefit from the industry's high-quality development initiatives [4] Profit Forecast - The company is projected to achieve net profits of 4.966 billion yuan, 5.249 billion yuan, and 5.563 billion yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 2.71 yuan, 2.86 yuan, and 3.03 yuan, indicating a positive growth trajectory [4][5]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company reported a stable performance with a slight decrease in revenue of 0.46% to 4.372 billion yuan and a net profit decline of 6.33% to 662 million yuan for the first half of 2024. However, the net profit after excluding non-recurring items increased by 6.31% to 735 million yuan [5] - The traditional Chinese medicine segment showed steady performance, while the negative impact from the centralized procurement of chemical drugs has been fully reflected. The approval of new indications for biological drugs is expected to bring a turning point [5] - The company’s modern Chinese medicine R&D pipeline is rich, with two products in the production application stage and 19 products in clinical II and III phases, which are expected to become new growth points for revenue [5] - The revenue forecasts for 2024 to 2026 are 8.78 billion yuan, 9.43 billion yuan, and 10.11 billion yuan, with year-on-year growth rates of 1.2%, 7.4%, and 7.3% respectively. The net profit forecasts are 1.14 billion yuan, 1.36 billion yuan, and 1.64 billion yuan, with growth rates of 6.4%, 19.5%, and 20.2% respectively [5] Summary by Sections Company Basic Data - Latest closing price: 13.76 yuan - One-year high/low price: 17.67/12.24 yuan - Current P/E ratio: 20.03 - Current P/B ratio: 1.64 - Total shares: 1.494 billion - Total market value: 20.557 billion yuan [3] Performance Analysis - The company achieved a revenue of 4.372 billion yuan in H1 2024, with a slight decline of 0.46%. The net profit attributable to shareholders was 662 million yuan, down 6.33%, while the net profit after excluding non-recurring items was 735 million yuan, up 6.31% [5] - Traditional Chinese medicine revenue was 3.121 billion yuan, an increase of 3.53%. Chemical drug revenue was 631 million yuan, up 12.57%, while biological drug revenue was 107 million yuan, down 7.75% [5] Profit Forecast - The company’s revenue and net profit forecasts for 2024 to 2026 are as follows: - Revenue: 87.80 billion yuan (2024), 94.26 billion yuan (2025), 101.10 billion yuan (2026) - Net profit: 11.40 billion yuan (2024), 13.62 billion yuan (2025), 16.37 billion yuan (2026) [7]

[Table_Rank] 评级： 看好 [Table_Authors] 李田 分析师 SAC 执证编号：S0110522090002 litian11@sczq.com.cn [Table_Chart] 市场指数走势（最近 1 年） -0.4 -0.2 0 0.2 商贸零售 沪深300 28-Aug 8-Nov19-Jan 31-Mar 11-Jun 22-Aug 资料来源：聚源数据 相关研究 [Table_OtherReport] 商社周报：7 月社零有所恢复，阿里 京东业绩、指引靓丽 商社周报：食品带动 7 月 CPI 上行， 资生堂业绩受核污水拖累 周报： 亚马逊财报显示海外需求回 落，餐饮盈利多承压 [Table_Title] 商社周报：中报密集发布，关注结构性机会 [Table_ReportDate] 商贸零售 | 行业简评报告 | 2024.08.27 核心观点 [Table_Summary] ⚫ 周度行情：本周（2024.8.19-2024.8.25）主要宽基指数下跌。上证综 指数下跌 0.87%，深证成指下跌 2.01%，创业板指下跌 2.80%。商贸 零售子板块方面， 细分行业均下跌。其中专 ...